×

Cesca Therapeutics to Present Progress on Its CellWerks(TM) Product Pipeline at the AABB Conference in Anaheim, California, October 24-27

RANCHO CORDOVA, Calif., Oct. 23, 2015 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that it will be presenting at the annual American Association of Blood Banks conference in Anaheim, California October 24-27. The poster, entitled "Volume Reduction and RBC Depletion of Apheresis Products for Cryopreservation," will report progress of research using Cesca's AutoXpress® technology platform in nucleated cell purification of apheresis product, the nucleated cells being the primary component of blood used for treating blood-based cancers such as leukemia. Apheresis is a process that removes one component of blood (for example white blood cells) while returning the remaining components (red blood cells and plasma) to the donor. The process is currently the main methodology for concentrating hematopoietic stem cells for transplantation.

"This project is one of several in Cesca's current CellWerks™ pipeline advancing the application of our AutoXpress technology for rapidly evolving needs in hematology/oncology," stated Mitchel Sivilotti, Senior VP and Chief Biologist for Cesca Therapeutics. "As ex vivo cell expansion technology matures, our technology is being positioned to address advanced therapeutic and bioprocessing protocols across multiple sources of potent, viable hematopoietic cells. We are very encouraged by these results and recent collaborations, they create lasting value in our next generation products."

About Cesca Therapeutics Inc.

Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the research, development and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. These include:

  • SurgWerks™; proprietary stem cell therapy point-of-care kits for the treatment of vascular and orthopedic indications that integrate the following indication specific elements:
    • Cell harvesting
    • Cell processing and selection
    • Cell diagnostics
    • Cell delivery
  • CellWerksTM; an integrated system which includes a protocol, disposables and equipment for intra-laboratory use in treatment of oncological and hematological disorders.
  • The AutoXpress® (AXP); a proprietary automated device, along with companion sterile blood processing disposables, for the harvesting of stem cells from cord blood.
  • The MarrowXpress (MXP); a device and disposable system based on the AutoXpress platform for the isolation and concentration of stem cells from bone marrow. Self-powered and microprocessor-controlled, the MXP contains flow control and optical sensors and concentrates white blood cells from bone marrow to a user-defined volume in 40 minutes while retaining over 90% of mononuclear cells (MNCs).
  • The BioArchive® System; an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries, for cryopreservation and archiving of cord blood stem cell units for transplant.

Forward Looking Statement

The statements contained herein may include statements of future expectations and other forward looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements, including our ability to initiate and prosecute the pivotal CLIRST III trial, our ability to obtain efficacy consistent with prior CLI studies, continued FDA approval, Medicare reimbursement approval, timing of the Company's future submission of IDE, PMA and/or Medicare reimbursement applications, or amendments to such applications, and outcomes from such submissions. Further, clinical trial outcomes are not predictable, and results may vary from the Company's expectations, including the start of any such clinical trials, patient follow up issues, and costs associated with such trials. Further description of other risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements. Contact: Cesca Therapeutics Inc. http://www.cescatherapeutics.com. Cesca may, at its discretion, choose to publish on-going interim notifications, requests for further information as received from the FDA, Medicare or equivalent foreign agencies, but as a general policy only makes announcements regarding material or significant information, such as filing of applications, approvals, initiation of studies, and conclusions.

CONTACT: Cesca Therapeutics Inc. http://www.cescatherapeutics.com Investor Contact: Kirin Smith, PCG Advisory Group 646-863-6519, or ir@cescatherapeutics.com Media Contact: Sean Leous, PCG Advisory Group 646-863-8998 or sleous@pcgadvisory.com

Source:Cesca Therapeutics Inc.